Figure 3From: CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal modelsCNX-013-B2 reduces blood glucose and lipid levels. A- Fasting (6 h) glucose in DIO mice. B- Fed glucose in ob/ob mice. C- Fasting TG in DIO mice. D- Fasting TG in ob/ob mice. E- Total cholesterol and F-LDLc. All the values are expressed as Mean ± SEM; one way analysis of variance followed by Dunnett’s test for representing significance value of the treatment groups. P value significance was represented as (*) <0.05, (**) <0.01 and (***) <0.001 when compared with DIO control. (#) <0.05 and (###) <0.001 as compared to lean or ob/+.Back to article page